Samsung Biologics (KRX:207940) signed a biologics contract manufacturing organization (CMO) contract with an unnamed US-based pharmaceutical company, according to a Tuesday filing with the Korea Exchange.
The contract, valued at 1.8 trillion won, is valid from Aug. 29, 2025, to Dec. 31, 2029.
Shares of Samsung Biologics rose more than 2% in recent trade.